Mural Oncology plc financial data

Symbol
MURA on Nasdaq
Industry
Pharmaceutical Preparations
Location
10 Earlsfort Terrace, Dublin 2, Ireland
State of incorporation
Ireland
Fiscal year end
December 31
Former names
Mural Oncology Ltd (to 8/24/2023)
Latest financial report
10-Q - Q2 2024 - Aug 13, 2024

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 725 %
Debt-to-equity 19.2 %
Return On Equity -99.5 % -107%
Return On Assets -83.5 %

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 17M shares
Common Stock, Shares, Outstanding 16.9M shares
Entity Public Float 81.4M USD
Common Stock, Value, Issued 169K USD
Weighted Average Number of Shares Outstanding, Basic 16.9M shares +1.41%
Weighted Average Number of Shares Outstanding, Diluted 16.9M shares +1.41%

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense 137M USD -35.2%
General and Administrative Expense 36.1M USD +42.3%
Operating Income (Loss) -173M USD +27.5%
Income Tax Expense (Benefit) 6.94M USD -100%
Net Income (Loss) Attributable to Parent -173M USD +11.5%
Earnings Per Share, Basic -10.3 USD/shares +38.2%
Earnings Per Share, Diluted -10.3 USD/shares +38.2%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 122M USD
Other Assets, Current 628K USD
Assets, Current 213M USD
Property, Plant and Equipment, Net 9.71M USD
Operating Lease, Right-of-Use Asset 10.1M USD
Other Assets, Noncurrent 61K USD
Assets 235M USD
Accounts Payable, Current 3.11M USD
Employee-related Liabilities, Current 4.55M USD
Accrued Liabilities, Current 16.2M USD
Liabilities, Current 24.6M USD
Operating Lease, Liability, Noncurrent 5.73M USD
Other Liabilities, Noncurrent 0 USD -100%
Liabilities 30.4M USD
Retained Earnings (Accumulated Deficit) -93.3M USD
Stockholders' Equity Attributable to Parent 205M USD
Liabilities and Equity 235M USD

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -37.3M USD +33%
Net Cash Provided by (Used in) Investing Activities -125M USD -31191%
Common Stock, Shares Authorized 450M shares
Common Stock, Shares, Issued 16.9M shares
Common Stock, Par or Stated Value Per Share 0.01 USD/shares
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect -162M USD
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 124M USD
Deferred Tax Assets, Valuation Allowance 5.93M USD -95%
Operating Lease, Liability 11.1M USD
Depreciation 900K USD +28.6%
Payments to Acquire Property, Plant, and Equipment 55K USD -86.2%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -31.5M USD +37.1%
Lessee, Operating Lease, Liability, to be Paid 11.5M USD
Property, Plant and Equipment, Gross 45.1M USD
Operating Lease, Liability, Current 5.35M USD
Lessee, Operating Lease, Liability, to be Paid, Year Two 2.48M USD
Lessee, Operating Lease, Liability, to be Paid, Year One 6.64M USD
Operating Lease, Weighted Average Discount Rate, Percent 0.04 pure 0%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 420K USD
Lessee, Operating Lease, Liability, to be Paid, Year Three 2.48M USD
Deferred Tax Assets, Operating Loss Carryforwards 714K USD -99%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 50M shares
Unrecognized Tax Benefits 0 USD -100%
Additional Paid in Capital 298M USD
Preferred Stock, Shares Outstanding 0 shares
Deferred Tax Assets, Net of Valuation Allowance 3.32M USD -32.1%
Share-based Payment Arrangement, Expense 21.6M USD -62.1%
Preferred Stock, Par or Stated Value Per Share 0.01 USD/shares